Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.

L. Li, Yingzi Luan, Gangduo Wang, Bujian Tang, Danrong Li, Wei Zhang, Xiping Li, Jinshun Zhao, Hong Ding, Eddie Reed, Qingdi Q. Li

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Platinum agents and paclitaxel (taxol) are among the most effective drugs currently available for treatment of ovarian cancer. One of the hurdles with taxol and platinum- based therapy is the clinical development of resistance to these agents. To investigate the mechanism of drug resistance in human ovarian cancer, we developed and characterized 5 cell models for chemoresistance studies of cisplatin, carboplatin and taxol. We report in this study that these human ovarian carcinoma cell model systems include 2 models for cisplatin resistance, 2 models for carboplatin resistance, and 1 model for taxol resistance. The biological and biochemical characteristics of the models showed that (i), the IC50 values of the drugs for all these resistant cell models were 3 times (or more) higher than those for the parental tumor cells. There also exist varying degrees of cross-resistance to several other chemotherapeutic agents in these systems. Moreover, the intracellular drug accumulations in these cells were significantly reduced as compared to those in the parental cells. (ii), The proliferation rates of these resistant cells were markedly decreased. However, there were no obvious changes in cell cycle distribution in these model systems. (iii), Our results for the expression of a few major drug resistance-related genes revealed that the expression of p53, lrp-1 and mrp-1 was decreased, while the expression of pkc, topo I and topo II beta was increased in the resistant tumor cells as compared with the parental cells. In contrast, no significant alterations in gst-pi and topo II alpha expression were found. Interestingly, the levels of mdr-1 expression were elevated in some models, but were reduced in others, thus suggesting that different pathways are involved in the formation of drug resistance in different cell model systems, and that different mechanisms are responsible for the development of different drug resistances in tumor cells. Taken together, our findings indicate that these models may be potentially used to assess the biochemical and genetic mechanisms of drug resistance in human ovarian cancer and to identify new drug resistance-related genes.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalInternational Journal of Molecular Medicine
Volume14
Issue number2
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Carcinoma
Drug Resistance
Paclitaxel
Ovarian Neoplasms
Carboplatin
Platinum
Cisplatin
Pharmaceutical Preparations
Neoplasms
Inhibitory Concentration 50
Molecular Biology
Cell Cycle
Gene Expression
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. / Li, L.; Luan, Yingzi; Wang, Gangduo; Tang, Bujian; Li, Danrong; Zhang, Wei; Li, Xiping; Zhao, Jinshun; Ding, Hong; Reed, Eddie; Li, Qingdi Q.

In: International Journal of Molecular Medicine, Vol. 14, No. 2, 08.2004, p. 257-264.

Research output: Contribution to journalArticle

Li, L, Luan, Y, Wang, G, Tang, B, Li, D, Zhang, W, Li, X, Zhao, J, Ding, H, Reed, E & Li, QQ 2004, 'Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.', International Journal of Molecular Medicine, vol. 14, no. 2, pp. 257-264.
Li, L. ; Luan, Yingzi ; Wang, Gangduo ; Tang, Bujian ; Li, Danrong ; Zhang, Wei ; Li, Xiping ; Zhao, Jinshun ; Ding, Hong ; Reed, Eddie ; Li, Qingdi Q. / Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. In: International Journal of Molecular Medicine. 2004 ; Vol. 14, No. 2. pp. 257-264.
@article{f9d681d289cf4ca9baa351f60e498a78,
title = "Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.",
abstract = "Platinum agents and paclitaxel (taxol) are among the most effective drugs currently available for treatment of ovarian cancer. One of the hurdles with taxol and platinum- based therapy is the clinical development of resistance to these agents. To investigate the mechanism of drug resistance in human ovarian cancer, we developed and characterized 5 cell models for chemoresistance studies of cisplatin, carboplatin and taxol. We report in this study that these human ovarian carcinoma cell model systems include 2 models for cisplatin resistance, 2 models for carboplatin resistance, and 1 model for taxol resistance. The biological and biochemical characteristics of the models showed that (i), the IC50 values of the drugs for all these resistant cell models were 3 times (or more) higher than those for the parental tumor cells. There also exist varying degrees of cross-resistance to several other chemotherapeutic agents in these systems. Moreover, the intracellular drug accumulations in these cells were significantly reduced as compared to those in the parental cells. (ii), The proliferation rates of these resistant cells were markedly decreased. However, there were no obvious changes in cell cycle distribution in these model systems. (iii), Our results for the expression of a few major drug resistance-related genes revealed that the expression of p53, lrp-1 and mrp-1 was decreased, while the expression of pkc, topo I and topo II beta was increased in the resistant tumor cells as compared with the parental cells. In contrast, no significant alterations in gst-pi and topo II alpha expression were found. Interestingly, the levels of mdr-1 expression were elevated in some models, but were reduced in others, thus suggesting that different pathways are involved in the formation of drug resistance in different cell model systems, and that different mechanisms are responsible for the development of different drug resistances in tumor cells. Taken together, our findings indicate that these models may be potentially used to assess the biochemical and genetic mechanisms of drug resistance in human ovarian cancer and to identify new drug resistance-related genes.",
author = "L. Li and Yingzi Luan and Gangduo Wang and Bujian Tang and Danrong Li and Wei Zhang and Xiping Li and Jinshun Zhao and Hong Ding and Eddie Reed and Li, {Qingdi Q.}",
year = "2004",
month = "8",
language = "English (US)",
volume = "14",
pages = "257--264",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.

AU - Li, L.

AU - Luan, Yingzi

AU - Wang, Gangduo

AU - Tang, Bujian

AU - Li, Danrong

AU - Zhang, Wei

AU - Li, Xiping

AU - Zhao, Jinshun

AU - Ding, Hong

AU - Reed, Eddie

AU - Li, Qingdi Q.

PY - 2004/8

Y1 - 2004/8

N2 - Platinum agents and paclitaxel (taxol) are among the most effective drugs currently available for treatment of ovarian cancer. One of the hurdles with taxol and platinum- based therapy is the clinical development of resistance to these agents. To investigate the mechanism of drug resistance in human ovarian cancer, we developed and characterized 5 cell models for chemoresistance studies of cisplatin, carboplatin and taxol. We report in this study that these human ovarian carcinoma cell model systems include 2 models for cisplatin resistance, 2 models for carboplatin resistance, and 1 model for taxol resistance. The biological and biochemical characteristics of the models showed that (i), the IC50 values of the drugs for all these resistant cell models were 3 times (or more) higher than those for the parental tumor cells. There also exist varying degrees of cross-resistance to several other chemotherapeutic agents in these systems. Moreover, the intracellular drug accumulations in these cells were significantly reduced as compared to those in the parental cells. (ii), The proliferation rates of these resistant cells were markedly decreased. However, there were no obvious changes in cell cycle distribution in these model systems. (iii), Our results for the expression of a few major drug resistance-related genes revealed that the expression of p53, lrp-1 and mrp-1 was decreased, while the expression of pkc, topo I and topo II beta was increased in the resistant tumor cells as compared with the parental cells. In contrast, no significant alterations in gst-pi and topo II alpha expression were found. Interestingly, the levels of mdr-1 expression were elevated in some models, but were reduced in others, thus suggesting that different pathways are involved in the formation of drug resistance in different cell model systems, and that different mechanisms are responsible for the development of different drug resistances in tumor cells. Taken together, our findings indicate that these models may be potentially used to assess the biochemical and genetic mechanisms of drug resistance in human ovarian cancer and to identify new drug resistance-related genes.

AB - Platinum agents and paclitaxel (taxol) are among the most effective drugs currently available for treatment of ovarian cancer. One of the hurdles with taxol and platinum- based therapy is the clinical development of resistance to these agents. To investigate the mechanism of drug resistance in human ovarian cancer, we developed and characterized 5 cell models for chemoresistance studies of cisplatin, carboplatin and taxol. We report in this study that these human ovarian carcinoma cell model systems include 2 models for cisplatin resistance, 2 models for carboplatin resistance, and 1 model for taxol resistance. The biological and biochemical characteristics of the models showed that (i), the IC50 values of the drugs for all these resistant cell models were 3 times (or more) higher than those for the parental tumor cells. There also exist varying degrees of cross-resistance to several other chemotherapeutic agents in these systems. Moreover, the intracellular drug accumulations in these cells were significantly reduced as compared to those in the parental cells. (ii), The proliferation rates of these resistant cells were markedly decreased. However, there were no obvious changes in cell cycle distribution in these model systems. (iii), Our results for the expression of a few major drug resistance-related genes revealed that the expression of p53, lrp-1 and mrp-1 was decreased, while the expression of pkc, topo I and topo II beta was increased in the resistant tumor cells as compared with the parental cells. In contrast, no significant alterations in gst-pi and topo II alpha expression were found. Interestingly, the levels of mdr-1 expression were elevated in some models, but were reduced in others, thus suggesting that different pathways are involved in the formation of drug resistance in different cell model systems, and that different mechanisms are responsible for the development of different drug resistances in tumor cells. Taken together, our findings indicate that these models may be potentially used to assess the biochemical and genetic mechanisms of drug resistance in human ovarian cancer and to identify new drug resistance-related genes.

UR - http://www.scopus.com/inward/record.url?scp=16644379905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644379905&partnerID=8YFLogxK

M3 - Article

C2 - 15254775

AN - SCOPUS:16644379905

VL - 14

SP - 257

EP - 264

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 2

ER -